Status:
COMPLETED
Osteosarcoma1999-A Study Of Intensive Chemotherapy for Osteosarcoma
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborating Sponsors:
Immunex/Berlex
National Institutes of Health (NIH)
Conditions:
Osteosarcoma
Eligibility:
All Genders
Up to 25 years
Phase:
PHASE2
Brief Summary
This trial (OS99) evaluates the use of ifosfamide, carboplatin, and doxorubicin in an up-front window before surgery for localized and resectable osteosarcoma. High-dose methotrexate, which may interf...
Detailed Description
This study has multiple research objectives: * To compare the response rate of pre-surgical chemotherapy comprised of ifosfamide, doxorubicin, and carboplatin to that obtained with ifosfamide and car...
Eligibility Criteria
Inclusion
- All subjects with histologically proven high-grade osteosarcoma,chondrosarcoma, MFH, fibrosarcoma or chondrosarcoma of bone, whose tumors are potentially resectable (either by limb sparing, en bloc resection, or amputation) and have no evidence of metastasis.
- Adequate liver, renal and cardiac function.
- Age: Younger than 25 years old
Exclusion
- Prior chemotherapy
Key Trial Info
Start Date :
May 1 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2006
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00145639
Start Date
May 1 1999
End Date
May 1 2006
Last Update
June 10 2011
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Arkansas Children's Hospital
Little Rock, Arkansas, United States, 72202
2
Washington University Medical Center
St Louis, Missouri, United States, 63110
3
St.Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105
4
Hospital Luis Calvo Mackenna
Santiago, Chile